Germ cell tumor: Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling

Radiology

Volumn 211, Issue 1, 1999, Pages 249-256

  Sugawara, Yoshifumi ^a   Zasadny, Kenneth R ^a   Grossman, H Barton ^b,c   Francis, Isaac R ^b   Clarke, Michael F ^a   Wahl, Richard L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Emission CT (ECT); Fluorine; Germ cell neoplasm; Glucose

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TERATOMA; TISSUE NECROSIS;

EID: 0032929519     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.211.1.r99ap16249     Document Type: Article

References (37)

1. Einhorn I.H, Richie JP, Shipley WV. Cancer of the testis. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 4th ed. Philadelphia, Pa: Lippincott, 1993; 1126-1151.
2. Saxman S. Salvage therapy in recurrent testicular cancer. Semin Oncol 1992; 19: 143-147.
3. Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992; 19:148-158.
4. Steyerberg EW, Keizer HJ, Stoter G, Habbema JD. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 1994; 30A:1231-1239.
5. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170:329-332.
6. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32:1655-1660.
7. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1932.
8. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
9. Wahl RL. Positron emission tomography: application in oncology. In: Murray IPC, Ell PJ, Strauss HW, eds. Nuclear medicine in clinical diagnosis and treatment. London, England: Livingstone, 1994; 801-820.
10. Wahl RL, Hawkins RA, Larson SM, et al. Proceedings of a National Cancer Institute workshop: PET in oncology - a clinical research agenda. Radiology 1994; 193: 604-606.
11. Wahl RL, Greenough R, Clarke MK, Grossman HB. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms (abstr). J Nucl Med 1993; 34(suppl):6P.
12. 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995; 22: 508-513.
13. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14:1637-1641.
14. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33:1234-1241.
15. Weber G. Enzymology of cancer cells. N Engl J Med 1977; 296:541-551.
16. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME. Quantitating tumor glucose metabolism with FDG and PET (editorial). J Nucl Med 1992; 33:339-344.
17. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995; 36:297-306.
18. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
19. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff E, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388.
20. Hawkins RA, Phelps ME, Huang SC. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab 1986; 6:170-183.
21. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33:333-339.
22. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36:1811-1817.
23. 18E]fluoro-D-glucose by direct nucleophilic exchange on a quatenary 4-aminopyridinium resin. Int J Radiat Appl Instrum [B] 1990; 17:273-279.
24. Minn H, Zasadny KR, Quint EE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196:167-173.
25. Zasadny KR, Wahl RE. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.
26. Germano G, Chen BC, Huang SC, Gambhir SS, Hoffman EJ, Phelps ME. Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies. J Nucl Med 1992; 33:613-620.
27. Marquardt DW. An algorithm for least squares estimation of nonlinear parameters. J Soc Indust Appl Math 1965; 11: 431-441.
28. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
29. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 1982; 50:1629-1635.
30. Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985; 56:860-863.
31. Loehrer PJ Sr, Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol 1986; 135:1183-1189.
32. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR 1985; 145:743-746.
33. Brodsky GL. Pathology of testicular germ cell tumors. Hematol Oncol Clin North Am 1991; 5:1095-1126.
34. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. S Nucl Med 1996; 37:371-374.
35. Henze E, Huang SC, Ratib O, Hoffman E, Phelps ME, Schelbert HR. Measurements of regional tissue and blood-pool radiotracer concentrations from serial tomographic images of the heart. J Nucl Med 1983; 24:987-996.
36. Herholz K, Patlak CS. The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography. J Cereb Blood Flow Metab 1987; 7:214-229.
37. Delaloye AB, Wahl RL. How high a level of FDG abdominal activity is considered normal (abstr). J Nucl Med 1995; 36(suppl): 106P.